What is Sinopharm COVID-19 Vaccine?

Sinopharm is authorised by the World Health Organization (WHO) for its emergency use listing, and received WHO validation for its safety, efficacy and quality.  WHO has thoroughly assessed the data on quality, safety and efficacy of the Sinopharm vaccine and has recommended its use for people aged 18 and above.

Efficacy and Safety Profile

The Sinopharm vaccine’s efficacy rate is currently at 79% in preventing symptomatic infection in the multi-country Phase 3 trial.  Vaccine efficacy against hospitalization was 79% (95%CI 26–94%).  This is compared to 51% for Sinovac’s and 95% for the Pfizer-BioNTech/Cominarty COVID-19 vaccine.  More studies are required to prove the BBIBP-CorV’s efficacy against COVID-19 variants.

HSA safety update #6 (30 December 2020 – 30 September 2021) – Incidence of Adverse Effects (AE)

  • Sinopharm 0.02% AE (none serious)
  • Sinovac 0.06% AE (0.005% serious)
  • mRNA 0.14% AE (0.006% serious), 81 local cases of myocarditis, pericarditis, 8.4 per 100,000 cerebral venous thrombosis.

How does the Sinopharm COVID-19 Vaccine work?

Sinopharm COVID-19 vaccines works like traditional vaccines, using inactivated virus to trigger our immune system to produce an immune response to fight against the virus. In comparison MRNA vaccines work by injecting the COVID-19 genetic code into the body, triggering the production of viral proteins that trains the immune system to defend against the virus

How can I book an appointment to receive the Sinopharm COVID-19 Vaccine?

  • Please use your own name, email, and contact number for booking of appointment as the slots are valid for individual bookings ONLY.
  • Book your vaccination appointment through the link below.
  • Upon confirmation of vaccination appointment, you will receive an email notification.
  • If you do not receive the email notification, please email our enquiry line at info@bethesdamedical.com.sg

Terms and Conditions

  • Booking of appointments can ONLY be done in the link above.
  • Please use your own name, email, and contact number for the booking of appointment.
  • People who meet these requirements will be eligible for Sinopharm COVID-19 vaccine. 
    • Above 18 years old
    • Do not have a history of anaphylaxis (serious life-threatening allergic reaction)to any components of the vaccine
    • If you are pregnant, please consult your obstetrician to assess your suitability for the vaccine.  Pregnant women with COVID-19 are at higher risk of developing severe disease than non-pregnant women of reproductive age. COVID-19 in pregnancy has also been associated with an increased risk of preterm birth and of neonates requiring intensive care.
    • Lactating women are eligible to be administered with the Sinopharm vaccine, and able to continue breastfeeding post-vaccination.
    • Those who have had COVID-19 in the past are eligible for vaccination post six months after COVID-19 infection.
    • Anyone with an acute febrile illness (body temperature over 38.5 ºC) should postpone vaccination until they are afebrile.

    Please consult our doctors if you are unsure about getting the vaccine. You may also refer to this MOH link for more information:

  • Ministry of Health Singapore recommends that persons who receive Sinopharm under the Special Access Route (SAR) are advised to receive a third dose of vaccine as a primary series. The recommended schedule is three doses (0.5 ml) given intramuscularly into the deltoid muscle. WHO recommends an interval of 3–4 weeks for the 2nd dose. The third dose should be taken 90 days after the second dose.
  • Persons who receive Sinopharm will only be considered fully vaccinated after completing the 3-dose primary series.

 

MOM maintains recommendations

  • Booster vaccine is recommended to be administered 3 months after a primary course of inactivated vaccine or after recovery from COVID-19 infection.

  1. How does Sinopharm vaccine work?

Sinopharm vaccine exposed the body to inactivated COVID-19 virus, to induce the immune system will make antibodies against the coronavirus, attaching to viral proteins. The delivery virus has been attenuated so you won’t develop the common cold when administered with this vaccine.  Your body immune system can then respond to an infection of live coronaviruses by producing antibodies to block the virus.

2.Why is it important to get the COVID-19 vaccine?

The Singapore government has advised that COVID-19 vaccination, together with safe distancing measures, contact tracing and proactive testing, will help to protect us and our loved ones against COVID-19. Vaccination will not only reduce the number of people susceptible to the coronavirus, but also reduce the chances of transmission in the community.  A high local vaccination coverage is key to protect ourselves from COVID-19, and we encourage all medically eligible persons to be vaccinated.

3. How effective is the Sinopharm vaccine?

The Sinopharm vaccine’s efficacy rate is currently at 79% in preventing symptomatic infection in the multi-country Phase 3 trial. This can be compared to 51% for the Sinovac vaccine and 95% for the Pfizer-BioNTech/Cominarty vaccine.  More studies are required to determine COVID-19 vaccine efficacy against COVID-19 variants.

4. Do you need a booster vaccine?

There has been evidence that antibody levels from COVID-19 vaccines, (mRNA vaccines, Sinovac and the Sinopharm BIBP vaccines) decline with time after two doses.  A third dose of booster vaccine increases this antibody response substantially.  The Expert Committee notes that some individuals have opted for Sinopharm BIBP under the Special Access Route (SAR) as their primary series vaccination and these individuals are also strongly recommended to take a third dose of COVID-19 vaccines for their primary series vaccination.  A third dose of the Sinopharm BIBP vaccine is recommended to be given at three months after the second dose to complete their primary vaccination series

5. Who should receive booster vaccination?

The Expert Committee on COVID-19 Vaccination (EC19V) has further recommended that the following persons should receive a booster dose of a COVID-19 vaccine from six months after the completion of the primary
series:
a. Healthcare and frontline workers aged 18 years and above
b. Persons and staff in institutionalised settings aged 18 years and above
c. Persons aged 30 years and above